Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merav Leiba

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
JCI Insight|February 8, 2023
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myelomaJana Jakubikova, Danka Cholujova, Gabor Beke, et al.
British Journal of Haematology|April 27, 2012
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agentsMerav Leiba, Jana Jakubikova, Steffen Klippel, et al.
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Genes, Chromosomes & Cancer|May 7, 2016
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?Merav Leiba, Adrian Duek, Ninette Amariglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 PathwayKatia Beider, Evgenia Rosenberg, Hanna Bitner, et al.
Anticancer Research|May 18, 2012
Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myelomaLisa Billecke, Eva Maria Murga Penas, Annette M May, et al.
International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
JCI Insight|February 8, 2023
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myelomaJana Jakubikova, Danka Cholujova, Gabor Beke, et al.
British Journal of Haematology|April 27, 2012
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agentsMerav Leiba, Jana Jakubikova, Steffen Klippel, et al.
Cancer Biology & Therapy|December 18, 2025
RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myelomaZuzana Valuskova, Dana Cholujova, Gabor Beke, et al.
Genes, Chromosomes & Cancer|May 7, 2016
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?Merav Leiba, Adrian Duek, Ninette Amariglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 PathwayKatia Beider, Evgenia Rosenberg, Hanna Bitner, et al.
Anticancer Research|May 18, 2012
Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myelomaLisa Billecke, Eva Maria Murga Penas, Annette M May, et al.
International Journal of Cancer|December 19, 2022
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemiaDanka Cholujova, Gabor Beke, Zachary R Hunter, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Pageof 7